Skip to content
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk
All contributors

Onconephrology contributor

Gratama, Jan W

Primarily Cellular therapy renal effects#41 of 46 recognized
  • #3 in Cellular therapy renal effects
4
Clinical papers
1,062
Citations (iCite)
0 / 3
First / senior author
2011–2016
Active years

Output over time

Clinical corpus papers per year — peak 2 in 2013.

  • 2011: 1 paper
  • 2013: 2 papers
  • 2016: 1 paper
20112016

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Cellular therapy renal effects4

Frequent co-authors

Other recognized contributors who most often share corpus papers with Gratama (shared-paper count).

Lamers, Cor H J4

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 27284065 (opens PubMed in a new tab)PMID 23423337 (opens PubMed in a new tab)PMID 23388583 (opens PubMed in a new tab)PMID 20889925 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.